Summary
41.83 1.49(3.69%)06/28/2024
Janux Therapeutics Inc (JANX)
Janux Therapeutics Inc (JANX)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 3.75 | 2.05 | -11.45 | 10.82 | 257.52 | 263.11 | 0.00 | 4,083.00 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 41.83 | |
| Open | 40.74 | |
| High | 42.15 | |
| Low | 40.63 | |
| Volume | 589,050 | |
| Change | 1.51 | |
| Change % | 3.75 | |
| Avg Volume (20 Days) | 488,798 | |
| Volume/Avg Volume (20 Days) Ratio | 1.21 | |
| 52 Week Range | 5.65 - 65.60 | |
| Price vs 52 Week High | -36.23% | |
| Price vs 52 Week Low | 640.35% | |
| Range | 2.68 | |
| Gap Up/Down | -0.25 | |
Fundamentals | ||
| Market Capitalization (Mln) | 2,172 | |
| EBIDTA | 0 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 35.00 | |
| Book Value | 9.1510 | |
| Earnings Per Share | -1.5570 | |
| EPS Estimate Current Quarter | -0.1800 | |
| EPS Estimate Next Quarter | -0.2000 | |
| EPS Estimate Current Year | -1.3600 | |
| EPS Estimate Next Year | -1.4200 | |
| Diluted EPS (TTM) | -1.5570 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | -10.4374 | |
| Return on asset (TTM) | 0.0000 | |
| Return on equity (TTM) | 0.0000 | |
| Revenue TTM | 2,021,000 | |
| Revenue per share TTM | 0.1500 | |
| Quarterly Revenue Growth (YOY) | 0.0000 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 0 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 2.1769 | |
| Revenue Enterprise Value | 214.1964 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 41,611,500 | |
| Shares Float | 13,453,417 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 11.00 | |
| Institutions (%) | 85.09 | |
04/17 13:12 EST - investorplace.com
Take the Money and Run: 3 Overbought Stocks to Sell ASAP
Generally, the idea of selling securities rankles the public's nerve, yet trimming overbought stocks is just as important a discipline as knowing what to buy. It might be even more important than the latter concept.
Take the Money and Run: 3 Overbought Stocks to Sell ASAP
Generally, the idea of selling securities rankles the public's nerve, yet trimming overbought stocks is just as important a discipline as knowing what to buy. It might be even more important than the latter concept.
04/16 13:19 EST - investorplace.com
These 3 Biotech Stocks Are Up 269% in 2024. Is There More to Come?
Investors looking for a white-knuckle ride can easily find one by buying biotech stocks. There is a certain thrill in investing in a company making actual life-or-death decisions with drugs.
These 3 Biotech Stocks Are Up 269% in 2024. Is There More to Come?
Investors looking for a white-knuckle ride can easily find one by buying biotech stocks. There is a certain thrill in investing in a company making actual life-or-death decisions with drugs.
04/15 13:55 EST - zacks.com
Janux (JANX) Rises Almost 50% in a Week on Buyout Rumors
Janux (JANX) stock surges after some reports claim that the company is exploring opportunities for a potential sale following buyout offers from big pharma companies.
Janux (JANX) Rises Almost 50% in a Week on Buyout Rumors
Janux (JANX) stock surges after some reports claim that the company is exploring opportunities for a potential sale following buyout offers from big pharma companies.
04/12 09:50 EST - zacks.com
Janux Therapeutics (JANX) is on the Move, Here's Why the Trend Could be Sustainable
If you are looking for stocks that are well positioned to maintain their recent uptrend, Janux Therapeutics (JANX) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Janux Therapeutics (JANX) is on the Move, Here's Why the Trend Could be Sustainable
If you are looking for stocks that are well positioned to maintain their recent uptrend, Janux Therapeutics (JANX) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
04/12 05:40 EST - fool.com
Why Janux Therapeutics Stock Is Crushing It This Week
Janux Therapeutics' stock jumped this week after a report stated the company was exploring a sale. The company hasn't publicly commented on whether it's involved in acquisition discussions.
Why Janux Therapeutics Stock Is Crushing It This Week
Janux Therapeutics' stock jumped this week after a report stated the company was exploring a sale. The company hasn't publicly commented on whether it's involved in acquisition discussions.
04/11 10:55 EST - zacks.com
Wall Street Analysts Think Janux Therapeutics (JANX) Could Surge 40.3%: Read This Before Placing a Bet
The mean of analysts' price targets for Janux Therapeutics (JANX) points to a 40.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts Think Janux Therapeutics (JANX) Could Surge 40.3%: Read This Before Placing a Bet
The mean of analysts' price targets for Janux Therapeutics (JANX) points to a 40.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
04/11 09:00 EST - seekingalpha.com
Janux Therapeutics: A Prime Target In Cancer Care's M&A Game
Janux Therapeutics' JANX007 shows promising Phase 1 data in treating advanced prostate cancer, with significant PSA level reductions. Early data suggest JANX007 could meet unmet needs in mCRPC treatment, with potential for dose optimization and safety balance. Amidst takeover speculation, Janux stock's valuation surged, yet I advise caution due to the speculative nature of acquisition outcomes.
Janux Therapeutics: A Prime Target In Cancer Care's M&A Game
Janux Therapeutics' JANX007 shows promising Phase 1 data in treating advanced prostate cancer, with significant PSA level reductions. Early data suggest JANX007 could meet unmet needs in mCRPC treatment, with potential for dose optimization and safety balance. Amidst takeover speculation, Janux stock's valuation surged, yet I advise caution due to the speculative nature of acquisition outcomes.
04/10 18:39 EST - fool.com
Why Janux Therapeutics Stock Soared as the Market Sagged Today
According to a media report, among other potential moves, the biotech is considering putting itself up for sale. It has apparently received buyout offers from pharmaceutical companies.
Why Janux Therapeutics Stock Soared as the Market Sagged Today
According to a media report, among other potential moves, the biotech is considering putting itself up for sale. It has apparently received buyout offers from pharmaceutical companies.
04/08 10:35 EST - zacks.com
After Plunging -11.78% in 4 Weeks, Here's Why the Trend Might Reverse for Janux Therapeutics (JANX)
Janux Therapeutics (JANX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
After Plunging -11.78% in 4 Weeks, Here's Why the Trend Might Reverse for Janux Therapeutics (JANX)
Janux Therapeutics (JANX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
03/28 13:01 EST - zacks.com
Janux Therapeutics (JANX) Upgraded to Buy: Here's What You Should Know
Janux Therapeutics (JANX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Janux Therapeutics (JANX) Upgraded to Buy: Here's What You Should Know
Janux Therapeutics (JANX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
03/22 10:55 EST - zacks.com
Wall Street Analysts Believe Janux Therapeutics (JANX) Could Rally 57.47%: Here's is How to Trade
The mean of analysts' price targets for Janux Therapeutics (JANX) points to a 57.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts Believe Janux Therapeutics (JANX) Could Rally 57.47%: Here's is How to Trade
The mean of analysts' price targets for Janux Therapeutics (JANX) points to a 57.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
03/20 13:44 EST - benzinga.com
Cancer-Focused Janux Therapeutics Platform Has 'Tremendous Opportunity': Analyst - Janux Therapeutics (NASDAQ:JANX)
Cantor Fitzgerald initiated coverage on Janux Therapeutics Inc JANX, citing the company's TRACTr/TRACir platform to target numerous tumor antigens and cancer types.
Cancer-Focused Janux Therapeutics Platform Has 'Tremendous Opportunity': Analyst - Janux Therapeutics (NASDAQ:JANX)
Cantor Fitzgerald initiated coverage on Janux Therapeutics Inc JANX, citing the company's TRACTr/TRACir platform to target numerous tumor antigens and cancer types.
03/15 09:45 EST - fool.com
2 Stocks That Have More Than Tripled This Year: Are They Buys?
Viking Therapeutics and Janux Therapeutics are flying high on the back of positive data readouts. However, there is a long road ahead and plenty of potential risks for both of these mid-cap biotechs.
2 Stocks That Have More Than Tripled This Year: Are They Buys?
Viking Therapeutics and Janux Therapeutics are flying high on the back of positive data readouts. However, there is a long road ahead and plenty of potential risks for both of these mid-cap biotechs.
03/08 16:01 EST - businesswire.com
Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights.
Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights.
03/02 06:56 EST - fool.com
After Soaring 222% in 1 Day, Is Janux Therapeutics Stock a Buy?
Janux Therapeutics just reported some phenomenal early Phase 1 data. It still needs to confirm the value of its programs and platform.
After Soaring 222% in 1 Day, Is Janux Therapeutics Stock a Buy?
Janux Therapeutics just reported some phenomenal early Phase 1 data. It still needs to confirm the value of its programs and platform.
03/01 10:31 EST - zacks.com
5 Stocks That More Than Doubled in February
Janux Therapeutics (JANX), SoundHound (SOUN), ROOT, Equillium (EQ) and CleanSpark (CLSK) more than doubled in February.
5 Stocks That More Than Doubled in February
Janux Therapeutics (JANX), SoundHound (SOUN), ROOT, Equillium (EQ) and CleanSpark (CLSK) more than doubled in February.
03/01 09:51 EST - zacks.com
Recent Price Trend in Janux Therapeutics, Inc. (JANX) is Your Friend, Here's Why
If you are looking for stocks that are well positioned to maintain their recent uptrend, Janux Therapeutics, Inc. (JANX) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Recent Price Trend in Janux Therapeutics, Inc. (JANX) is Your Friend, Here's Why
If you are looking for stocks that are well positioned to maintain their recent uptrend, Janux Therapeutics, Inc. (JANX) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
02/29 01:22 EST - businesswire.com
Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants.
Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants.
02/27 17:15 EST - seekingalpha.com
Janux: Additional Opportunity With JANX007 Dosing Update In The 2nd Half Of 2024
Janux Therapeutics, Inc. has positive preliminary results released from phase 1a study, using JANX007 for the treatment of patients with advanced or metastatic castration-resistant prostate cancer. With positive single-agent activity of JANX007 observed in patients with metastatic castration-resistant prostate cancer, potential to advance combination therapy with PSMA targeting agent XTANDI. It is expected that the global prostate cancer therapeutics market could reach $28.5 billion by 2032.
Janux: Additional Opportunity With JANX007 Dosing Update In The 2nd Half Of 2024
Janux Therapeutics, Inc. has positive preliminary results released from phase 1a study, using JANX007 for the treatment of patients with advanced or metastatic castration-resistant prostate cancer. With positive single-agent activity of JANX007 observed in patients with metastatic castration-resistant prostate cancer, potential to advance combination therapy with PSMA targeting agent XTANDI. It is expected that the global prostate cancer therapeutics market could reach $28.5 billion by 2032.
02/27 17:00 EST - businesswire.com
Janux Therapeutics Announces Proposed Public Offering of Common Stock
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Announces Proposed Public Offering of Common Stock.
Janux Therapeutics Announces Proposed Public Offering of Common Stock
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Announces Proposed Public Offering of Common Stock.